Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. Guidelines for the management of hemophilia. Haemophilia. 2013 Jan;19(1):e1-47. doi: 10.1111/j.1365-2516.2012.02909.x. Epub 2012 Jul 6. PubMed PMID: 22776238.
Laffan MA, Lester W, O'Donnell JS, et al. The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology. Br J Haematol. 2014 Nov;167(4):453-65. doi: 10.1111/bjh.13064. Epub 2014 Aug 12. Review. PubMed PMID: 25113304; PubMed Central PMCID: PMC4283483.
Nichols WL, Hultin MB, James AH, et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia. 2008 Mar;14(2):171-232. doi: 10.1111/j.1365-2516.2007.01643.x. PubMed PMID: 18315614.
Inherited coagulation disorders are most frequently caused by a deficiency or dysfunction of one of the plasma coagulation factors (hemophilia A [factor VIII] or B [factor IX]). Inherited deficiencies of factor XII, prekallikrein, and high-molecular-weight kininogen cause prolongation of the activated partial thromboplastin time but are asymptomatic and require no treatment. Rare deficiencies of fibrinogen, prothrombin, and factors V, VII, X, XI, or XIII cause bleeding of varied severity. Treatment is based on replacement of the deficient coagulation factors.